MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: NEK7
MedXY News
EnglishTag

NEK7

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationcritical carebiomarkersartificial intelligencetype 1 diabetesclinical trialsHypertensiononcologyCardiologyMortalitypublic healthcardiovascular diseasediabetesAlzheimer's diseasebreast cancerepidemiology

Latest news

Tag

Targeting NEK7-Mediated EGFR Phosphorylation to Overcome Lenvatinib Resistance in Hepatocellular Carcinoma
GastroenterologyNEK7Lenvatinib resistance

Targeting NEK7-Mediated EGFR Phosphorylation to Overcome Lenvatinib Resistance in Hepatocellular Carcinoma

By MedXY|Aug 21, 2026

NEK7 promotes acquired lenvatinib resistance in hepatocellular carcinoma by phosphorylating EGFR at serine 1070, activating key signaling pathways. Blocking this interaction offers a promising therapeutic avenue to counteract resistance.

Targeting NEK7 with an Oral Molecular-Glue Degrader: MRT-8102 Advances an Upstream Inflammasome Strategy for Cardiovascular Inflammation
CardiologyatherosclerosisNEK7

Targeting NEK7 with an Oral Molecular-Glue Degrader: MRT-8102 Advances an Upstream Inflammasome Strategy for Cardiovascular Inflammation

By MedXY|Nov 12, 2025

Preclinical AHA 2025 data show MRT-8102, an oral NEK7-directed molecular glue degrader, selectively degrades NEK7, suppresses NLRP3 inflammasome activation and pyroptosis across species, and reduces multi-cytokine release—supporting Phase 1

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models